Reading : 2 minutes
EIC accelerator 2

The selected companies will receive grants and/or equity investments, depending on their needs, up to a maximum of EUR 17.5 million. They were selected following a rigorous process, introduced under Horizon Europe, involving an ideas screening stage, and full applications assessed by external experts and an interview with a jury of experienced investors and entrepreneurs.

The selected companies have a wide geographical spread spanning 21 countries, including seven from Horizon Europe “widening countries” that have lower levels of research and innovation performance. The selection also confirms the high demand for EIC equity investments with 65 of the 99 companies requesting equity investments of up to EUR 414 million (out of the total EUR 627 million). In most cases, the companies will receive the grant financing within the coming months, while the equity investment is likely to take longer as the arrangements for implementing EIC equity need to be re-established under Horizon Europe. This delay will also affect companies selected in the previous funding round.

For more information: https://eic.ec.europa.eu/news/largest-ever-funding-round-european-innovation-council-accelerator-99-innovative-companies-set-2021-12-16_en.

Suggested articles

logo Nature article

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min
Bio Boston 2023

NETRIS Pharma attending the Bio International Convention in Boston (June 5-8, 2023)

NETRIS Pharma, a clinical-stage immuno-oncology pharmaceutical company pioneering NETRIN-1-based drug discovery and development, is confirming today that CEO and Founder Patrick Mehlen, and CFO Christophe Guichard, will be attending the Bio International Convention taking place June 5-8, 2023, in Boston, MS. Meet with us at the Partnering booth ! For any information, please send an email to christopheguichard@netrispharma.com

Reading : 1 min

NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137

Lap-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with m_FOLFIRINOX for first line patients with Locally Advanced Pancreatic Ductal Adenocarcinoma

Reading : 5 min